Davina Bledsoe
Nurse Practitioner · Coos Bay, ORNPI 1295245108
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $746 and has fallen 91.4% since, to $64 in 2025. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$570
- AbbVie$426
- Novartis$281
- Amgen$142
- E.r. Squibb & Sons, L.L.C.$124
- Pfizer$123
- plus $828 from 23 others
What the payments were for
- Food & beverage$2,47099%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $570 |
| AbbVie | 36 | $426 |
| Novartis | 14 | $281 |
| Amgen | 8 | $142 |
| E.r. Squibb & Sons, L.L.C. | 18 | $124 |
| Pfizer | 7 | $123 |
| Sanofi Pasteur Inc. | 4 | $69 |
| Novo Nordisk | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Astellas Pharma US Inc | 3 | $57 |
| Ultragenyx Pharmaceutical Inc. | 3 | $56 |
| Edwards Lifesciences | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Bayer | 3 | $44 |
| Kyowa Kirin, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Exact Sciences | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Sanofi | 1 | $28 |
| Biowound Solutions, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Organon | 1 | $13 |
How this compares
$2,494 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $138,942 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $86,987 |
| OzempicSemaglutide | 69 | $78,977 |
| TrulicityDulaglutide | 28 | $34,615 |
| Nurtec OdtRimegepant Sulfate | 18 | $33,555 |
| JardianceEmpagliflozin | 29 | $29,690 |
| MyrbetriqMirabegron | 18 | $22,259 |
| XareltoRivaroxaban | 18 | $21,511 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,018 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $14,255 |
| QuliptaAtogepant | 11 | $12,582 |
| Lurasidone Hcl | 11 | $10,701 |
| Repatha SureclickEvolocumab | 12 | $10,049 |
| Atorvastatin Calcium | 544 | $7,965 |
| Gabapentin | 292 | $6,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $123 | $172,497127 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $570 | $92,023131 claims |
| Novo NordiskOzempic | $68 | $78,97769 claims |
| Lilly USA, LLCTrulicity | $18 | $34,61528 claims |
| Boehringer IngelheimJardiance | $15 | $29,69029 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $22,25918 claims |
| AbbVieQulipta | $426 | $12,58211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.
Other nurse practitioner in Coos Bay
- Margaret McLainCoos Bay$8K
- Jason EmpsonCoos Bay$2K
- Alicia DuyvejonckSpringfield$299K
- Summer HarnessLake Oswego$113K
- Alana WilsonPortland$58K
- Jennifer MurdochPortland$15K
- Berhane MebratuPortland$10K
- Desiree CihelkaSpringfield$8K
- Amy CarterPortland$8K
- Mallory CrownoverSpringfield$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.